Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aspira Women's Health Announces Publication Of Data Demonstrating Performance Of Its In-Development Blood Test For The Assessment Of Malignancy Risk In Patients With An Adnexal Mass

Author: Benzinga Newsdesk | September 10, 2024 08:14am

Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlighting data demonstrating that a multimodal assay combining miRNA with protein biomarkers, age, and menopausal status offered the most accurate classification of patients with an adnexal mass for the identification of early-stage ovarian cancer.

Posted In: AWH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist